Aims: Abstinence among alcohol dependent liver graft recipients is remarkably high. The routine use of anti-immune agents in these patients led to rodent studies showing that immunosuppressants acting through inhibition of calcineurin (CLN) are highly effective in decreasing alcohol consumption. It remained unclear, however, whether the decreased alcohol consumption in rodent models is mediated through peripheral suppression of immune response or centrally through direct inhibition of cyclophilin-CLN in the brain. We tested the hypothesis that direct brain inhibition of CLN with intracerebroventricular (ICV) injections of the immunosuppressant cyclosporine A (CsA) is sufficient to decrease ethanol consumption in a rodent model of binge-like drinking. Methods: Male C57BL/6NHsd mice were put through a modified 'drinking in the dark' (DID) paradigm. Effects of both peripheral (IP) and central (ICV) injections of CsA on ethanol consumption were assessed. Results: Here, as in earlier work, IP CsA administration significantly decreased alcohol consumption. Supporting our hypothesis, central administration of CsA was sufficient to decrease alcohol consumption in a dose-dependent manner. There was no significant effect of CsA on water or sucrose consumption. Conclusions: These results clearly implicate a CLN-mediated mechanism in brain in the inhibitory effects of CsA on ethanol consumption and provide novel targets for investigation of treatment for Alcohol Use Disorders (AUD). These results also add to the growing body of literature implicating neuroimmune mechanisms in the etiology, pathophysiology and behaviors driving AUD. Short Summary: The unusually high abstinence rate and routine use of immunosuppressants in AUD liver graft recipients led us to rodent studies showing that immunosuppressants acting through inhibition of calcineurin (CLN) are highly effective in decreasing drinking. Here we demonstrate that this effect is mediated by brain rather than peripheral immune mechanisms.
INTRODUCTION
Liver graft recipients with alcohol use disorder (AUD) show a surprisingly high rate of abstinence (Lucey, 2007; DiMartini et al., 2010) . Approximately 90% are abstinent 1 year after transplant and about 75-80% after 3 years. This is remarkable when compared to rates from other treatment studies demonstrating abstinence rates at 1 year closer to 35-45% (Yates et al., 1993; Allen et al., 1995) . We initially hypothesized that this high abstinence among liver transplant patients could be explained by pre-transplant AUD case selection and/ or post-transplant psychosocial factors known to facilitate abstinence (Lucey et al., 1994) . However, these factors could not account for the persistent high abstinence rates among AUD liver graft recipients (Beresford et al., 1992 (Beresford et al., , 1990 Beresford, 1997) . One common factor among these patients is the near universal use of immunosuppressants such as cyclosporine A (CsA) post-transplant. We considered the possibility that these immunosuppressants could be playing a role in promoting abstinence.
We were the first to report an effect of immunosuppressants on alcohol drinking in an animal model. Mice treated with CsA drank significantly less ethanol in a controlled, continuous-access, twobottle choice model while having no effect on total liquid intake (Beresford et al., 2005) . We sought to determine the mechanism of this effect by comparing three different immunosuppressants acting though different modes of action in a modified 'drinking in the dark' (DID) paradigm of excessive drinking (Beresford et al., 2012) . Again, immunosuppressants were highly effective in decreasing alcohol consumption, but only those acting through inhibition of the phosphatase calcineurin (CLN) and that crossed the blood-brain barrier. CsA and tacrolimus (FK-506) inhibit CLN activity through different mechanisms but both decreased ethanol consumption. A third immunosuppressant, sirolumus (SRL) that acts through CLNindependent pathways had no effect on ethanol consumption. Though inhibition of CLN was clearly implicated, it was still unclear whether the anti-drinking effects were due to suppression of peripheral immune responses through CLN inhibition or direct inhibition of CLN in brain or via another mechanism in brain. Both CsA and TRL crossed the blood-brain barrier in this study. They also have known inhibitory effects on CLN in brain where immunophilins and calcineurin are abundant and widespread (Dawson et al., 1994) . Sirolimus did not effectively penetrate brain suggesting that a general suppression of peripheral immune function was not sufficient to decrease excessive alcohol consumption.
We sought to determine in these experiments if this CLNmediated inhibitory effect on drinking is acting via suppression of peripheral immune response or acting directly in the central nervous system (CNS). We hypothesized that central administration of CsA via intracerebroventricular (ICV) injection would be sufficient to inhibit excessive drinking behavior similar to what we have observed after peripheral administration (IP). The goal of this study was to assess the effects of inhibition of brain calcineurin, separate from any immunosuppressant effect, on ethanol drinking in a mouse model of binge-like drinking. We hypothesized that centrally (ICV) administered Cyclosporine A (CsA) would reduce alcohol consumption in a drinking in the dark model.
MATERIALS AND METHODS

Animals
Adult male C57BL/6NHsd mice (8 weeks; Envigo, Barrier 208 A, Frederick, MD) were initially housed five per group (Microvent Positive Ventilated Housing, Allentown Inc., Allentown, NJ) on a reversed light cycle (off 9:00 AM: on 9:00 PM) in a temperature controlled (23 ± 1°C) AALAC approved animal facility at the Sioux Falls VA. Mice were given ad libidum access to food and water. Ethanol consumption in the DID model has been shown to be significantly altered depending on the variety of standard rodent chow chosen (Marshall et al., 2015 
Materials
Ethanol (190 proof, Fisher Scientific) and sucrose (Sigma-Aldrich) were mixed with tap water to 20% (v/v) and 10% (w/v) solutions, respectively. All solutions were made fresh daily. Cyclosporine A (LC Laboratories, Woburn, MA) was dissolved in 85% DMSO (vehicle). Doses of CsA (30 mg/kg IP, 15 and 30 μg ICV) were based on previous work demonstrating that 30 mg/kg IP was the most effective dose in reducing ethanol consumption in similar ethanol drinking model in mice (Beresford et al., 2012) and studies showing a range of behavioral and physiological effects of ICV CsA (Dougherty and Dafny, 1988; Francischi et al., 1997; AlmeidaCorrea et al., 2015) .
ICV cannulation
Guide cannulae were surgically implanted to allow for ICV injections. Mice were placed in an induction chamber and briefly exposed to isoflurane (5%). Mice were removed and anesthesia was maintained using a nosecone. Ketorolac (5 mg/kg, SC) was administered and their scalps shaved. They were then transferred to a stereotaxic unit (Kopf Model 962 Ultra Precise Small Animal Stereotaxic Instrument, David Kopf Instruments, Tujunga, CA) equipped with a gas anesthesia head holder (Model 923-B). Isoflurane anesthesia was maintained at 1.5-2.5% and the pedal response was continually checked to ensure adequate sedation. The scalp was scrubbed with a chlorhexidine solution followed by sterile saline. An incision was made in the scalp and tissue clamps applied to expose the skull. Fascia was scored and scraped to the sides of the skull with a scalpel and a hydrogen peroxide solution (3%) was applied. Stereotaxic coordinates targeting the lateral ventricle (AP: −0.46; ML: 1.0; DV: 2.3) were determined (Franklin and Paxinos, 2013) . With the aid of a surgical stereomicroscope on an articulating arm, a mark was made with surgical ink at these coordinates using a sterile needle attached to an electrode holder (Model 1770). A precision drill (Model 1474 High Speed Stereotaxic Drill; David Kopf Instruments, Tuluma, CA) with a sterile burr bit was used to drill through the skull at this mark, being careful to leave the dura intact. Dura and any remaining bone disc were gently removed using a sterile 25-g needle. Two more holes were drilled anterior and posterior and anchor screws inserted (1.6 diameter × 1.6 mm length; Plastics One). A guide cannula (26-g, C315GA, Plastics One, Roanoke, VA) was inserted into a cannula holder, lowered into the hole and secured in place with a self-curing acrylic resin (OrthoJet Acrylic, Lang Dental, Wheeling, IL). A dummy cannula was inserted and the incision was closed with sutures (simple interrupted, silk, 3.0) and an antibiotic cream applied to the wound. Mice were allowed to recover for 2 weeks before any further experimental procedures were performed.
Drinking in the dark
Rodent models of ethanol drinking involving voluntary consumption are limited in their ability to generate blood ethanol concentrations (BEC) believed to be pharmacologically meaningful in regard to characteristics of binge-drinking patterns (Thiele and Navarro, 2014) . We employed a 'drinking in the dark' paradigm (DID) that has been reported to work well inducing BEC of 0.08 (80 mg/100 ml of blood) (Rhodes et al., 2005; . This model promotes bingelike excessive ethanol consumption during a limited access schedule (2-4 h) during the peak activity period in the dark phase. It has shown predictive face validity for binge-like ethanol drinking in humans (Kamdar et al., 2007; . We used a slightly modified 2-day version of the DID procedure .
Briefly, during Week 1 mice were acclimated to handling and modified sipper tubes and given 4 days of alcohol access without any drug treatment. We created custom sipper tubes both to accurately measure consumption and to reduce any leakage as described by . Briefly, stainless steel bearing sipper tubes (Ancare Corp.) were inserted into polystyrene 10 ml graduated serological pipets (Fisher Scientific) and sealed with heat shrink tubing. Silicone stoppers (Fisher, European size 10D) were used to seal the opposite end. All tubes were tested for leakage. Binder clips were used to attach the tubes to the cages to prevent leakage as mice will climb on them.
On Day 1 homecage water bottles were removed at the start of the dark period and replaced with the custom pipette sipper tubes filled with water. Water bottles were replaced after 8 h. On Days 2-5, homecage water bottles were removed and replaced with a 20% ethanol solution for 2 h, and 3 h into the dark phase. We and others have noted that extra days of ethanol access increase average alcohol consumption Figure 1 . The DID procedure was carried out on Days 9 and 10. Again, they were given 2 h access to 20% ethanol 3 h into the dark phase. On Day 10, CsA or Vehicle was administered 30 min prior to ethanol access and consumption over 2 h was measured. Two hours was chosen because it has been shown that during the second week of DID procedures mice 'front-load' their intake and consume roughly half of the total volume consumed over 4 h in the first 30 min (Wilcox et al., 2014) . We used the same 2-day DID model with 10% sucrose or water in place of EtOH to avoid bias when assessing the effects of CsA on alcohol consumption. All mice were weighed before the dark period on the first day of ethanol access and those weights were used to calculate consumption on the following days.
To verify ICV injections, mice were anesthetized and 2.0 μl methylene-blue was injected ICV using identical procedures to those used during the experiment. Brains were removed, frozen on dry ice and sectioned on a cryostat microtome (Cryostar NX70, Thermo Fisher Scientific). Injections were verified by the presence of dye in ventricles.
Statistics
Data were analyzed using SigmaStat 4.0 and graphed with SigmaPlot 10.0 (Systat Software Inc., San Jose, CA). Analysis of Variance (ANOVA) tests were used for all experiments (α = 0.05). Bonferonni Post-hoc tests were used if a significant interaction or main effect of drug was observed. All data are expressed as mean ± SEM.
RESULTS
Cyclosporine significantly decreased ethanol consumption whether given peripherally (IP) or centrally in brain (ICV). There was a significant main effect for treatment, F(4,32) = 6.17, P < 0.001. We repeated earlier findings demonstrating that a 30 mg/kg IP dose of CsA decreases ethanol intake in a DID model (P = 0.006). Here we show that central administration of CsA also decreases ethanol intake in a similar fashion (30 μg dose, P = 0.002). Though the mean consumption was slightly less for ICV vehicle compared to IP vehicle groups this difference was not significant (P = 0.467). There were no significant main effects of ICV or IP administration of CsA on consumption of sucrose, F(4,31) = 0.927, P = 0.461, or water, F(4,31) = 1.594, P = 0.201. Access to alcohol for 2 h session for 4 days in the week prior to the DID procedure significantly increased overall ethanol consumption, F(4,32) = 6.299, P = 0.003 (Figs 2-4) .
DISCUSSION
This experiment demonstrated that central administration of cyclosporine A is sufficient to decrease alcohol intake in mice in a binge-drinking model of ethanol consumption in a dose-dependent fashion. These results combined with our previous research (Beresford et al., 2012) Fig. 1. Ethanol intake increased over a 4 day access period. Mice were given access to 20% ethanol for 2 h/day for 4 days; *P = 0.011. clearly show that the anti-drinking effects of CsA are mediated by direct effects in brain and not by peripheral immunosuppression.
We also replicated and extended earlier findings demonstrating that peripheral administration (IP) of CsA significantly reduces alcohol intake (Beresford et al., 2005 (Beresford et al., , 2012 ) using a slightly different mouse strain and drinking model. Administration of CsA in brain is sufficient to decrease ethanol consumption suggesting that the effects seen after peripheral administration are due to direct actions in brain as well. Additionally, the fact that there were no significant effects of CsA on water or sucrose consumption indicates a specific effect of CsA on ethanol intake. An indiscriminate antidipsic effect cannot explain the results of this study nor can a reduced need for caloric intake or generalized taste aversion mechanism. The specific pathways mediating this effect still need to be elucidated. Suppression of neuroimmune activation is one hypothesis.
As an immunosuppressant, CsA acts in brain much like it does in peripheral immune cells. Similar to its role in peripheral immune/ inflammatory cells, CLN plays an integral role in processes regulating neuroimmune function. Calcineurin regulates glial cell activation and cytokine expression and is induced during disease, injury and aging (Furman and Norris, 2014) . Calcineurin is a major regulator of immune or inflammatory processes in both T-cells and glial cells through activation of the nuclear factor of activated T-cells (NFAT) family of transcription factors. Cyclosporine binds the immunophilin cyclophilin and this complex then inhibits the activity of CLN, a Ca 2+ and calmodulin-dependent serine-threonine phosphatase also known as protein phosphatase 3 (PPP3) (Liu et al., 1991) . Dephosphorylation of NFAT by CLN causes activation and nuclear translocation where it stimulates transcription of a number of proinflammatory genes including interleukin-2 (Clipstone and Crabtree, 1993; Ho et al., 1996; Musson and Smit, 2011) . It is now widely accepted that immune mechanisms, and specifically neuroimmune mechanisms, play important, if poorly understood, roles in the etiology and progression of alcohol abuse (Mayfield and Harris, 2017) . The hypothesis that an overactive neuroimmune system promotes alcohol consumption is gaining widespread support among scientists (Mayfield et al., 2013; Cui et al., 2014; Crews et al., 2017) . The first mention of a possible connection between immunosuppressants and alcohol consumption was published as a brief clinical report in 1990 (Giles et al., 1990) . It was noted that AUD liver graft patients were more abstinent while on immunosuppressants. It has taken many years for the research community to embrace and investigate this possibility.
Our 2005 study, stemming from insights gained from liver graft recipients, was the first to test the hypothesis that suppression of immune processes could limit ethanol intake (Beresford et al., 2005) . This notion has been extended by a number of other groups in the last few years. A range of compounds or genetic approaches that inhibit neuroimmune function have been shown to limit ethanol intake to varying degrees in a variety of animal models (Mayfield et al., 2013; Cui et al., 2014; Crews et al., 2017) . These studies target different specific mechanisms but they all converge on the common outcome of reducing neuroimmune activation. Along with reducing neuroinflammation, CsA also plays key roles in neuronal signaling processes.
The effectiveness of CsA in reducing ethanol consumption seen in this and our past studies may be due to its complementary roles in other brain signaling pathways related to brain reward and addiction. During the past few decades, the diverse and important roles CLN plays in neuronal signaling processes have been more and more appreciated. Calcineurin is one of the most abundant phosphatases in brain and is known to play important roles in a wide variety of signal transduction pathways. Not only involved in neuroimmune processes, CLN is also expressed at especially high levels in the brain in neurons. There are particularly high concentrations of CLN in the hippocampus, neocortex, striatum and amygdala (Furman and Norris, 2014) where CLN modulates diverse cellular functions including receptor and ion channel trafficking, ion channel function, apoptosis and gene regulation (Baumgartel and Mansuy, 2012) . Calcineurin is also abundantly expressed in all of the regions of the brain where CaMKII is found including the dopaminergic reward pathway of the ventral tegmental area (VTA) and the nucleus accumbens (NAc) (Sola et al., 1999) .
Calcineurin directly regulates dopaminergic and other monoaminergic signaling. Along with direct effects on monoamine synthesis and release it has been shown that CLN activity regulates an important dopamine and addiction-related signal transduction proteindopamine and cAMP-regulated neuronal phosphoprotein (DARPP-32). This protein regulates both dopaminergic and glutaminergic Fig. 4 . Cyclosporine had no effect water intake. There were no significant differences in water consumption between groups. Experimental groups: ICV vehicle, ICV CsA Low (15 μg), ICV CsA High (30 μg), IP Vehicle, IP CsA (30 mg/kg). Fig. 3 . Cyclosporine had no effect on sucrose intake. There were no significant differences in sucrose consumption between groups. Experimental groups: ICV vehicle, ICV CsA Low (15 μg), ICV CsA High (30 μg), IP Vehicle, IP CsA (30 mg/kg).
(NMDA) receptor responses in extended brain reward pathways (Greengard et al., 1999; Svenningsson et al., 2004) and is critically involved in regulating responses to ethanol and other drugs of abuse (Donohue et al., 2005; Svenningsson et al., 2005) . DARPP-32 is a direct CLN substrate. Dopamine causes increased phosphorylation and CN acts to maintain low levels of phosphorylated DARPP (Nishi et al., 1999) . It has been hypothesized that CsA inhibition of CLN acts as a dopamine mimetic via dopamine-like increases in phosphorylated DARPP-32 (Wera and Neyts, 1994) . In this way CLN inhibition could potentially dampen temporally linked dopamine reward cues elicited by alcohol and thereby lessen reinforcement.
Monoaminergic activity is integral to processes related to reward and addiction and CLN has been shown to regulate monoaminergic signaling. In rats, CsA alone has an inhibitory effect on monoamine production but, interestingly, when given along with a chronic stressor it has the opposite effect, leading to enhanced tissue levels of serotonin and norepinephrine (Fujisaki et al., 2003) . It also had antidepressant-like activity in the unpredictable chronic stress model that paralleled imipramine.
Calcineurin regulates several other signaling pathways known to be associated with addiction and stress including corticotropin releasing factor (CRF). While playing a critical role in the regulation of behavior and neuroendocrine responses to stress, CRF has also proven to be a significant contributor to the processes of alcohol consumption and abuse (Heilig and Koob, 2007; Ronan and Summers, 2011; Phillips et al., 2015) . Calcineurin regulates CRF gene expression and CRF-mediated behaviors. Transcription of CRF is mediated via cAMP response element binding protein (CREB) phosphorylation. Phosphorylation of CREB is necessary but not sufficient for CRF transcription (Liu et al., 2008) . A CLN-regulated coactivator called TORC (tranducer of regulated CREB activity) is also needed for CREB-induced CRF transcription (Liu et al., 2010; Spencer and Weiser, 2010) . Dephosphorylation of TORC by CLN facilitates translocation to the nucleus where it interacts with the dimerization and DNA binding domain of CREB and facilitates the recruitment of the preinitiation complex. This, in turn, facilitates transcriptional activation of CREB-dependent genes including CRF. CLN activity is required for depolarization-induced CREB-dependent gene transcription in cortical neurons (Kingsbury et al., 2007) . Stress alone induces nuclear translocation of TORC and transcription of CRF in rodents (Liu et al., 2011) . This TORC mediated mechanism for enhanced stress-induced CRF expression may underlie the enhanced sensitivity to stressors seen in models of ethanol abuse. Cyclosporine blocks CRF-receptor mediated catecholamine synthesis and release through inhibition of NFAT activation in cell culture (Dermitzaki et al., 2012) . CRF has been shown to modulate brain reward function directly through signaling in the ventral tegmental area, nucleus accumbens and the prefrontal cortex, among other structures (Ronan and Summers, 2011; Quadros et al., 2016) .
One of the strengths of this study is the use of a well-validated and widely used rodent drinking model. The 'drinking in the dark' procedure has high face validity as a model of human binge drinking (for review see, Thiele and Navarro, 2014) . Many strains of mice have the natural tendency to display excessive bouts of drinking under short term access to ethanol. The fact that they are not forced to drink as in other models of binge drinking (i.e. gavage, vapor, injection) can help us get at the underlying drinking behaviors. It also is not necessary in this model to deprive mice of food or water to study these drinking behaviors. Varying lines of evidence have converged to demonstrate that the high ethanol consumption in this model is not due to caloric need. This model has been successfully used to identify pharmacological targets and genetic mechanisms that promote binge drinking.
This study is an example of research going from clinical observations to the bench. The central question answered by this study, whether CsA acts centrally or peripherally to suppress alcohol consumption, could not have been answered in humans. The initial hypotheses gleaned from clinical observations lacked real proof. Empirical data on CsA and other immunosuppressants versus control with respect to suppression of alcohol consumption are not available in human studies. And performing a placebo controlled study in this population is ethically unfeasible. In this study we were able to employ a 'placebo'-controlled study design to properly assess the effects of CsA.
The steps from bench back to clinic: the need for mechanistic clarity While our mouse study data are remarkably encouraging in pursuing this innovative approach to treatment development, exploring this observed effect begins with an assessment of whether or not a similar effect actually occurs in people. The mouse data do not translate directly into human experiments with these agents. For one example, the effective mg/kg doses in mice would be toxic in human beings. For another, their immunosuppressant effects at standard doses given to transplant patients postoperatively cannot be clinically justified as a widespread treatment. In this regard, therefore, pursuing CLN inhibition as a new treatment option for AD first requires careful investigation with respect to specific mechanisms of action.
Identification of the specific pathways and substrates involved in this immunosuppressant effect on drinking needs to be studied taking a variety of approaches. One line of inquiry we are pursuing is to identify specific CLN pathways involved in this effect using a genetic approach. We are using conditional knockouts using both CreloxP and RNA interference techniques (Scammell et al., 2003; Callahan et al., 2013) , employing a transgenic mouse line with a floxed regulatory subunit of calcineurin (a generous gift from Dr. S. Tonegawa, MIT) along with 'cre-cutter' mouse lines and viral vectors, to determine the role of calcineurin-mediated pathways in specific brain regions and cell types (e.g. dopaminergic, glia). These studies and others investigating intracellular CLN substrates and downstream pathways will yield information that will allow us to target specific aspects of CLN signaling to better enable us to develop effective treatments with minimal side effects.
CONCLUSIONS
Our results clearly implicate a central brain mechanism in the inhibitory effects of CsA on alcohol consumption. This provides a rich avenue for the pursuit of therapeutic targets for treatment of AUD in humans and adds to the growing body of evidence that various neuro-immuno-modulatory pathways could provide novel targets for the development of pharmacotherapies for AUD (Coller and Hutchinson, 2012; Cui et al., 2014) . Cyclosporine itself is not a viable treatment option given its possible long-term nephrotoxicity and range of adverse side effects. Deciphering the specific proximal mechanisms underlying the anti-drinking effects of CsA holds the promise for the development of effective treatments where few exist. 
